Literature DB >> 2256435

Hepatic drug metabolism is increased in poorly controlled insulin-dependent diabetes mellitus.

S Goldstein1, A Simpson, P Saenger.   

Abstract

In addition to increased glycosylation of hemoglobin, abnormalities of other heme proteins such as cytochrome P-450 might also occur in patients with insulin-dependent diabetes mellitus. Antipyrine is a useful marker drug for cytochrome P-450 dependent hepatic drug metabolism. Antipyrine kinetics and urinary excretion of antipyrine metabolites were measured in 14 patients with insulin-dependent diabetes mellitus in poor metabolic control. Improvement in diabetic control in 9 patients, as measured by more normal HbA1 values, led to normalization of plasma antipyrine half-time (t1/2) and metabolism: the mean antipyrine t1/2 slowed from 4.7 +/- 0.2 (SEM) initially to 7.8 +/- 0.3 h in these 9 patients and was thus nearly identical to that of normal subjects 8.6 +/- 1.0. Antipyrine plasma clearance improved in the 9 diabetic patients whose diabetic control improved. The apparent volume of distribution was normal on both occasions in the diabetic patients. These findings provide a new argument for tight metabolic control in patients with insulin-dependent diabetes mellitus.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2256435     DOI: 10.1530/acta.0.1230550

Source DB:  PubMed          Journal:  Acta Endocrinol (Copenh)        ISSN: 0001-5598


  9 in total

Review 1.  Pregnane X receptor and constitutive androstane receptor at the crossroads of drug metabolism and energy metabolism.

Authors:  Jie Gao; Wen Xie
Journal:  Drug Metab Dispos       Date:  2010-08-24       Impact factor: 3.922

2.  Antipyrine disposition in obesity: evidence for negligible effect of obesity on hepatic oxidative metabolism.

Authors:  Y Caraco; E Zylber-Katz; E M Berry; M Levy
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

3.  Constitutive androstane receptor mediates the induction of drug metabolism in mouse models of type 1 diabetes.

Authors:  Bingning Dong; Mohammed Qatanani; David D Moore
Journal:  Hepatology       Date:  2009-08       Impact factor: 17.425

4.  Insulin-mimetic effects of vanadate in preventing the increase of P450IIIA and P450IA subfamily proteins in streptozotocin-diabetic rats.

Authors:  A Verrecchia; A Guaitani
Journal:  Acta Diabetol       Date:  1993       Impact factor: 4.280

5.  Effect of potent ethyl acetate fraction of Stereospermum suaveolens extract in streptozotocin-induced diabetic rats.

Authors:  T Balasubramanian; Tapan Kumar Chatterjee; G P Senthilkumar; Tamizh Mani
Journal:  ScientificWorldJournal       Date:  2012-04-19

6.  Modulation of CYP3a expression and activity in mice models of type 1 and type 2 diabetes.

Authors:  Dany Patoine; Michaël Petit; Sylvie Pilote; Frédéric Picard; Benoit Drolet; Chantale Simard
Journal:  Pharmacol Res Perspect       Date:  2014-09-01

Review 7.  Type 2 Diabetes and ADP Receptor Blocker Therapy.

Authors:  Matej Samoš; Marián Fedor; František Kovář; Michal Mokáň; Tomáš Bolek; Peter Galajda; Peter Kubisz; Marián Mokáň
Journal:  J Diabetes Res       Date:  2015-12-28       Impact factor: 4.011

8.  Glucose-dependent regulation of pregnane X receptor is modulated by AMP-activated protein kinase.

Authors:  Peter O Oladimeji; Wenwei Lin; C Trent Brewer; Taosheng Chen
Journal:  Sci Rep       Date:  2017-04-24       Impact factor: 4.379

Review 9.  Type 2 Diabetes, Atrial Fibrillation, and Direct Oral Anticoagulation.

Authors:  Dana Prídavková; Matej Samoš; Tomáš Bolek; Ingrid Škorňová; Jana Žolková; Peter Kubisz; Ján Staško; Marián Mokáň
Journal:  J Diabetes Res       Date:  2019-12-06       Impact factor: 4.011

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.